<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34372561</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>7</Issue><PubDate><Year>2021</Year><Month>Jul</Month><Day>13</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Environmental Surveillance for Risk Assessment in the Context of a Phase 2 Clinical Trial of Type 2 Novel Oral Polio Vaccine in Panama.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1355</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v13071355</ELocationID><Abstract><AbstractText>Environmental surveillance was recommended for risk mitigation in a novel oral polio vaccine-2 (nOPV2) clinical trial (M5-ABMG) to monitor excretion, potential circulation, and loss of attenuation of the two nOPV2 candidates. The nOPV2 candidates were developed to address the risk of poliovirus (PV) type 2 circulating vaccine-derived poliovirus (cVDPV) as part of the global eradication strategy. Between November 2018 and January 2020, an environmental surveillance study for the clinical trial was conducted in parallel to the M5-ABMG clinical trial at five locations in Panama. The collection sites were located upstream from local treatment plant inlets, to capture the excreta from trial participants and their community. Laboratory analyses of 49 environmental samples were conducted using the two-phase separation method. Novel OPV2 strains were not detected in sewage samples collected during the study period. However, six samples were positive for Sabin-like type 3 PV, two samples were positive for Sabin-like type 1 PV, and non-polio enteroviruses NPEVs were detected in 27 samples. One of the nOPV2 candidates has been granted Emergency Use Listing by the World Health Organization and initial use started in March 2021. This environmental surveillance study provided valuable risk mitigation information to support the Emergency Use Listing application.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rojas-Bonilla</LastName><ForeName>Magda</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hospital de Especialidades Pedi&#xe1;tricas, Servicio de Infectolog&#xed;a Pedi&#xe1;trica, Panama City, Panama.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coulliette-Salmond</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention, Division of Viral Diseases, Atlanta, GA 30329, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>United States Public Health Service, Rockville, MD 20852, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belgasmi</LastName><ForeName>Hanen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>IHRC, Inc., Atlanta, GA 30303, USA; Contracting Agency to the Division of Viral Diseases, Centers for Diseases Control and Prevention, Atlanta, GA 30329, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Kimberly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>IHRC, Inc., Atlanta, GA 30303, USA; Contracting Agency to the Division of Viral Diseases, Centers for Diseases Control and Prevention, Atlanta, GA 30329, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cherokee Nation Assurance, Tulsa, OK 74116, USA; Contracting Agency to the Division of Viral Diseases, Centers for Diseases Control, and Prevention, Atlanta, GA 30329, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sayyad</LastName><ForeName>Leanna</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cherokee Nation Assurance, Tulsa, OK 74116, USA; Contracting Agency to the Division of Viral Diseases, Centers for Diseases Control, and Prevention, Atlanta, GA 30329, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vega</LastName><ForeName>Everardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention, Division of Viral Diseases, Atlanta, GA 30329, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grimoldi</LastName><ForeName>Fabian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>DVM, Quality Assurance Manager, VacciNet, Panama City, Panama.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oberste</LastName><ForeName>M Steven</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention, Division of Viral Diseases, Atlanta, GA 30329, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>R&#xfc;ttimann</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Fighting Infectious Diseases in Emerging Countries, Miami, FL 33145, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012722">Sewage</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014612">Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D004784" MajorTopicYN="N">Environmental Monitoring</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010176" MajorTopicYN="N" Type="Geographic">Panama</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="N">Poliomyelitis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012722" MajorTopicYN="N">Sewage</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014612" MajorTopicYN="N">Vaccines</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">environmental surveillance</Keyword><Keyword MajorTopicYN="N">novel OPV2</Keyword><Keyword MajorTopicYN="N">polio</Keyword><Keyword MajorTopicYN="N">poliovirus</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>10</Day><Hour>1</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>7</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34372561</ArticleId><ArticleId IdType="pmc">PMC8310065</ArticleId><ArticleId IdType="doi">10.3390/v13071355</ArticleId><ArticleId IdType="pii">v13071355</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sutter R.W., Kew O.M., Cochi S.L., Aylward R.B. 49&#x2014;Poliovirus Vaccine&#x2013;Live. In: Plotkin S.A., Orenstein W.A., Offit P.A., Edwards K.M., editors. Plotkin&#x2019;s Vaccines. 7th ed. Elsevier; Amsterdam, The Netherlands: 2018. pp. 866&#x2013;917.e16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-323-35761-6.00048-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Comit&#xe9; Nacional de Certificaci&#xf3;n (Panama) Informe Anual: Documentaci&#xf3;n del Estatus de la Erradicaci&#xf3;n de la Polio. 2019. Unpublished Manuscript.</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative  Polio This Week as of 8 June 2021.  [(accessed on 10 June 2021)].  Available online:  https://Polioeradication.Org/Polio-Today/Polio-229Now/This-Week/Circulating-Vaccine-Derived-Poliovirus/</Citation></Reference><Reference><Citation>World Health Organization  . Statement of the Twenty-Sixth Polio IHR Emergency Committee. World Health Organization; Geneva, Switzerland: 2020.  [(accessed on 14 April 2021)].  Available online:  https://www.who.int/news/item/19-02-2021-statement-of-the-twenty-seventh-polio-ihr-emergency-committee.</Citation></Reference><Reference><Citation>Kalkowska D.A., Voorman A., Pallansch M.A., Wassilak S.G.F., Cochi S.L., Badizadegan K., Thompson K.M. The Impact of Disruptions Caused by the COVID-19 Pandemic on Global Polio Eradication. Vaccine. 2021 doi: 10.1016/j.vaccine.2021.04.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.04.026</ArticleId><ArticleId IdType="pmc">PMC10045205</ArticleId><ArticleId IdType="pubmed">33962838</ArticleId></ArticleIdList></Reference><Reference><Citation>Lickness J.S. Surveillance to Track Progress Toward Polio Eradication&#x2014;Worldwide, 2018&#x2013;2019. MMWR Morb. Mortal. Wkly. Rep. 2020;69 doi: 10.15585/mmwr.mm6920a3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6920a3</ArticleId><ArticleId IdType="pubmed">32437342</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P., Liu Y., Wang H., Liu G., Lin X., Zhang W., Ji F., Xu Q., Tao Z., Xu A. Environmental Surveillance Complements Case-Based Surveillance of Acute Flaccid Paralysis in Polio Endgame Strategy 2019&#x2013;2023. Appl. Environ. Microbiol. 2020;86 doi: 10.1128/AEM.00702-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AEM.00702-20</ArticleId><ArticleId IdType="pmc">PMC7376550</ArticleId><ArticleId IdType="pubmed">32444474</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P., Coster I.D., Bandyopadhyay A.S., Revets H., Withanage K., Smedt P.D., Suykens L., Oberste M.S., Weldon W.C., Costa-Clemens S.A., et al. The Safety and Immunogenicity of Two Novel Live Attenuated Monovalent (Serotype 2) Oral Poliovirus Vaccines in Healthy Adults: A Double-Blind, Single-Centre Phase 1 Study. Lancet. 2019;394:148&#x2013;158. doi: 10.1016/S0140-6736(19)31279-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)31279-6</ArticleId><ArticleId IdType="pmc">PMC6626986</ArticleId><ArticleId IdType="pubmed">31174831</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative  Continuing Innovation to Reach Every Last Child.  [(accessed on 3 June 2021)].  Available online:  https://Polioeradication.Org/News-Post/Continuing-Innovation-to-Reach-Every-Last-Child/</Citation></Reference><Reference><Citation>CDC Global Health-Immunization-Welcome to Poliopolis!  [(accessed on 3 June 2021)]; Available online:  https://www.cdc.gov/globalhealth/immunization/stories/welcome-to-poliopolis.html.</Citation></Reference><Reference><Citation>S&#xe1;ez-Llorens X., Bandyopadhyay A.S., Gast C., Leon T.D., DeAntonio R., Jimeno J., Caballero M.I., Aguirre G., Oberste M.S., Weldon W.C., et al. Safety and Immunogenicity of Two Novel Type 2 Oral Poliovirus Vaccine Candidates Compared with a Monovalent Type 2 Oral Poliovirus Vaccine in Children and Infants: Two Clinical Trials. Lancet Lond. Engl. 2021;397:27&#x2013;38. doi: 10.1016/S0140-6736(20)32540-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32540-X</ArticleId><ArticleId IdType="pmc">PMC7811205</ArticleId><ArticleId IdType="pubmed">33308427</ArticleId></ArticleIdList></Reference><Reference><Citation>Containment Advisory Group  Report of CAG TC3 on nOPV2 Candidate Vaccines and S19-Poliovirus Type 2 Strains 7 June 2018.  [(accessed on 30 January 2021)].  Available online:  https://polioeradication.org/wp-content/uploads/2017/08/CAG-TC3-20180630-EN.pdf.</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative  GPEI-Global Polio Laboratory Network Reports &amp; Publications.  [(accessed on 28 January 2021)].  Available online:  https://Polioeradication.Org/Tools-and-Library/Policy-Reports/Gpln-Publications/</Citation></Reference><Reference><Citation>World Health Organization  Guidelines for Environmental Surveillance of Poliovirus Circulation.  [(accessed on 1 February 2021)].  Available online:  https://apps.who.int/iris/handle/10665/67854.</Citation></Reference><Reference><Citation>Gerloff N., Sun H., Mandelbaum M., Maher C., Nix W.A., Zaidi S., Shaukat S., Seakamela L., Nalavade U.P., Sharma D.K., et al. Diagnostic Assay Development for Poliovirus Eradication OK. J. Clin. Microbiol. 2018;56:e01624-17. doi: 10.1128/JCM.01624-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.01624-17</ArticleId><ArticleId IdType="pmc">PMC5786708</ArticleId><ArticleId IdType="pubmed">29212703</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  Poliomyelitis.  [(accessed on 14 April 2021)].  Available online:  https://www.who.int/immunization/monitoring_surveillance/burden/vpd/WHO_SurveillanceVaccinePreventable_18_Polio_R2.pdf?ua=1.</Citation></Reference><Reference><Citation>Caja de Seguro Social Panama  Campa&#xf1;a de Vacunaci&#xf3;n Contra el Polio en Panama Oeste, Super&#xf3; la Meta Trazada | CSS Panam&#xe1;.  [(accessed on 7 June 2021)].  Available online:  http://www.css.gob.pa/web/8-noviembre-2019ah.html.</Citation></Reference><Reference><Citation>de Oliveira Pereira J.S., da Silva L.R., de Meireles Nunes A., de Souza Oliveira S., da Costa E.V., da Silva E.E. Environmental Surveillance of Polioviruses in Rio de Janeiro, Brazil, in Support to the Activities of Global Polio Eradication Initiative. Food Environ. Virol. 2016;8:27&#x2013;33. doi: 10.1007/s12560-015-9221-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12560-015-9221-5</ArticleId><ArticleId IdType="pmc">PMC4752579</ArticleId><ArticleId IdType="pubmed">26538420</ArticleId></ArticleIdList></Reference><Reference><Citation>Coulliette-Salmond A.D., Alleman M.M., Wilnique P., Rey-Benito G., Wright H.B., Hecker J.W., Miles S., Pe&#xf1;aranda S., Lafontant D., Corvil S., et al. Haiti Poliovirus Environmental Surveillance. Am. J. Trop. Med. Hyg. 2019;101:1240&#x2013;1248. doi: 10.4269/ajtmh.19-0469.</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.19-0469</ArticleId><ArticleId IdType="pmc">PMC6896891</ArticleId><ArticleId IdType="pubmed">31701857</ArticleId></ArticleIdList></Reference><Reference><Citation>Asghar H., Diop O.M., Weldegebriel G., Malik F., Shetty S., El Bassioni L., Akande A.O., Al Maamoun E., Zaidi S., Adeniji A.J., et al. Environmental Surveillance for Polioviruses in the Global Polio Eradication Initiative. J. Infect. Dis. 2014;210((Suppl. 1)):S294&#x2013;S303. doi: 10.1093/infdis/jiu384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu384</ArticleId><ArticleId IdType="pmc">PMC10578309</ArticleId><ArticleId IdType="pubmed">25316848</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  First Ever Vaccine Listed under WHO Emergency Use.  [(accessed on 11 February 2021)].  Available online:  https://www.who.int/news/item/13-11-2020-first-ever-vaccine-listed-under-who-emergency-use.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>